Results 101 to 110 of about 29,283 (270)
Journal of Surgical Oncology, EarlyView.ABSTRACT Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers.
Kristin E. Goodsell +5 more
wiley +1 more source
Contemporary Use of ctDNA for the Colorectal Surgeon
Clinics in Colon and Rectal SurgeryAbstractWhile advances in treatment and diagnostics have improved prognosis in colorectal cancer (CRC), room for advancement remains, highlighting the importance of improving tools for early detection and treatment guidance. Current national guidelines rely on stage-based treatment recommendations but fail to identify patients with lower stage disease ...
Heit, Madilyn, Cohen, Stacey A.
openaire +2 more sources
Journal of Surgical Oncology, EarlyView.ABSTRACT Pelvic lymph node dissection is an essential component of radical cystectomy (RC) for bladder cancer (BC), but the optimal extent of lymphadenectomy remains uncertain. We conducted a systematic review and meta‐analysis to compare oncologic and perioperative outcomes between extended and non‐extended lymphadenectomy during RC for BC.
Maria Fernanda Dias Azevedo +12 more
wiley +1 more source
Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics [PDF]
Blood AdvancesAbstract Positron emission tomography–computed tomography (PET-CT) is recommended for response evaluation in aggressive large B-cell lymphoma (LBCL) but cannot detect minimal residual disease (MRD). Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for real-time disease monitoring.
Gayaththri Vimalathas +12 more
openaire +4 more sources
Journal of Surgical Oncology, EarlyView.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis despite surgical resection, yet the prognostic literature remains fragmented across hundreds of single‐institution studies that vary in design, covariates, and analytical approaches.
Muhammad Maisam Ali +8 more
wiley +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu +2 more
wiley +1 more source
, 2017 Samuel J Klempner,1,2 Pareen Mehta,3 Alexa B Schrock,4 Siraj M Ali,4 Sai-Hong Ignatius Ou5 1The Angeles Clinic and Research Institute, Los Angeles, CA, USA; 2Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA;
Schrock AB +4 more
core
Prognostic impact of positive baseline ctDNA.
, 2016 (A) PFS and (B) OS in patients with positive and negative ctDNA (n = 105).
Eleonora Zonta (3153192) +11 more
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Response to neoadjuvant chemoradiotherapy (NACRT) in locally advanced colorectal cancer (CRC) varies widely, and accurately identifying poor responders is crucial for guiding timely treatment modification. This study aimed to develop an integrated predictive model combining radiomics derived from routine radiotherapy non‐contrast planning ...
Sin‐Hua Moi +6 more
wiley +1 more source
Precision Medical Sciences, EarlyView.Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik +4 more
wiley +1 more source